- Home
- PMAX vs APLM Comparison
PMAX vs APLM Comparison
Compare PMAX & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- APLM
- Stock Information
- Founded
- PMAX 2019
- APLM 2016
- Country
- PMAX Hong Kong
- APLM United States
- Employees
- PMAX N/A
- APLM N/A
- Industry
- PMAX
- APLM Blank Checks
- Sector
- PMAX
- APLM Finance
- Exchange
- PMAX Nasdaq
- APLM Nasdaq
- Market Cap
- PMAX 6.7M
- APLM 6.1M
- IPO Year
- PMAX 2024
- APLM N/A
- Fundamental
- Price
- PMAX $0.26
- APLM $5.16
- Analyst Decision
- PMAX
- APLM
- Analyst Count
- PMAX 0
- APLM 0
- Target Price
- PMAX N/A
- APLM N/A
- AVG Volume (30 Days)
- PMAX 1.9M
- APLM 36.1K
- Earning Date
- PMAX 10-17-2025
- APLM 09-19-2025
- Dividend Yield
- PMAX N/A
- APLM N/A
- EPS Growth
- PMAX N/A
- APLM N/A
- EPS
- PMAX N/A
- APLM N/A
- Revenue
- PMAX $4,694,079.00
- APLM $198,000.00
- Revenue This Year
- PMAX N/A
- APLM $415.15
- Revenue Next Year
- PMAX N/A
- APLM N/A
- P/E Ratio
- PMAX N/A
- APLM N/A
- Revenue Growth
- PMAX N/A
- APLM N/A
- 52 Week Low
- PMAX $0.23
- APLM $3.66
- 52 Week High
- PMAX $4.70
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- PMAX 31.60
- APLM 46.73
- Support Level
- PMAX $0.30
- APLM $3.66
- Resistance Level
- PMAX $0.33
- APLM $6.37
- Average True Range (ATR)
- PMAX 0.05
- APLM 0.56
- MACD
- PMAX -0.01
- APLM -0.06
- Stochastic Oscillator
- PMAX 12.43
- APLM 55.37
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.